Etelcalcetide hydrochloride (also known as AMG 416) is a new, second generation, long-acting calcimimetic agent that is administered intravenously. In November 2016 it received its first approval in the UE for the treatment of secondary hyperparathyroidism (SHPT) in adult haemodialysis patients.
This article summarizes the results of pre-clinical and clinical studies which demonstrated that Etelcalcetide decreases effectively PTH levels. Although questions about this new compound remain open, and further studies are required to assess clinical hard outcomes as well as long term efficacy and safety, Etelcalcetide represents a new therapeutic option for the challenging treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
BlairH.A.Etelcalcetide: first global approval.Drugs.2016: 76(18): 1787–1792.
4.
AlexanderS.T., HunterT., WalterS.. Critical Cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action.Mol Pharmacol.2015: 88: 853–865.
5.
WalterS., BaruchA., AlexanderS.T.. Comparison of AMG 416 and Cinacalcet in rodent models of uremia.BMC Nephrol.2014; 15(1): 81.
6.
WalterS., BaruchA., DongJ.. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.J Pharmacol Exp Ther.2013; 346: 229–240.
7.
MartinJ.M., BellG., PickhornK.. Velcalcetide (AMG 416), a novel peptide agonist of calcium-sensing receptor, reduces parathyroid hormon and FGF23 levels in healthy male subjects.Nephrol Dial Transplant.2014; 29: 385–392.
8.
BlockG.A., MartinK.J., de FranciscoA.L.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.N Engl J Med.2004; 350: 1516–1525.
9.
GinchermanY., MoloneyK., McKeeC., CoyneD.W.Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients.Hemodial Int.2010; 14: 68–72.
10.
SubramanianR., ZhuX., HockM.B.. Phamacokinetics, bio-transformation and excretion of [14C]Etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis.Clin Pharmacokinet.2017; 56(2): 179–192.
11.
NemethE.F., GoodmanW.G.Calcimimetic and calcilytic drugs: feats, flops and futures.Calcif Tissue Int.2016; 98: 341–358.
12.
MartinK.J., PickthornK., HuangS.. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.Kidney Int.2013; 85: 191–197.
13.
BlockG.A., BushinskyD.A., CunninghamJ.. Effect of etelcalcitide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials.JAMA.2017; 317(2): 146–155.
FukagawaM., YokoyamaK., ShigematsuT.. A phase 3, multicentre, randomized, double-blind, placebo controlled parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/ AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialsis patients.Nephrol Dial Transplant.2017. Jan 5; [Epub ahead of print].
16.
LissK., BlockG.A., ChertowG.M., DehmelB., SunY., SpiegelD.M.Initiation of AMG 416 After Discontinuation of Cinacalcet. ASN Annual Meeting; November 3–8 2015; San Diego. Abstract TH-PO516. J Am Soc Nephrol.2015; 26: (Abstract Supplement).
17.
BlockG.A., BushinskyD.A., ChengS.. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial.JAMA.2017; 317(2): 156–164.
18.
MiddletonJ.P., WolfM.Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.JAMA.2017; 317(2): 139–141.
19.
BushinskyD.A., BlockG.A., ChengS.. One year efficacy and safety of intravenous (IV) etelcalcetide (AMG 416) in patients on hemodialysis (HD) with secondary hyperparathyroidism (SHPT). Abstract SO030 at 53rd Congress ERA-EDTA; May 21–24 2016; Vienna, Austria. Nephrol Dial Transplant.2016; 31(Suppl. 1); i13–14.
